Literature DB >> 2785905

Pharmacokinetics of ranitidine in critically ill infants.

D B Wiest1, W O'Neal, J R Reigart, R C Brundage, P C Gillette, R L Yost.   

Abstract

The pharmacokinetic parameters of ranitidine were studied following administration of a single intravenous dose in 9 critically ill infants. Ranitidine disposition was best described by a biphasic elimination curve. For 8 patients, the mean values for T1/2, apparent volume of distribution, and total body clearance were 2.09 h, 1.61 l/kg, and 13.93 ml/min/kg, respectively. Based on simulated steady-state concentration profiles, a dose of 0.7 mg/kg administered intravenously every 6 h should maintain serum levels above 40 ng/ml for 4.7 h of the dosing interval with a wide degree of variability.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2785905

Source DB:  PubMed          Journal:  Dev Pharmacol Ther        ISSN: 0379-8305


  10 in total

1.  Cross-over trial of treatment for bradycardia attributed to gastroesophageal reflux in preterm infants.

Authors:  Eva Wheatley; Kathleen A Kennedy
Journal:  J Pediatr       Date:  2009-06-21       Impact factor: 4.406

Review 2.  Clinical pharmacokinetics of drugs used in the treatment of gastrointestinal diseases (Part II).

Authors:  K Lauritsen; L S Laursen; J Rask-Madsen
Journal:  Clin Pharmacokinet       Date:  1990-08       Impact factor: 6.447

3.  Long-term gastric pH monitoring for determining optimal dose of ranitidine for critically ill preterm and term neonates.

Authors:  A L Kuusela
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1998-03       Impact factor: 5.747

4.  Famotidine. Pharmacokinetic properties and suppression of acid secretion in paediatric patients following cardiac surgery.

Authors:  G Kraus; D R Krishna; D Chmelarsch; M Schmid; U Klotz
Journal:  Clin Pharmacokinet       Date:  1990-01       Impact factor: 6.447

Review 5.  Clinical Pharmacology Studies in Critically Ill Children.

Authors:  Nilay Thakkar; Sara Salerno; Christoph P Hornik; Daniel Gonzalez
Journal:  Pharm Res       Date:  2016-09-01       Impact factor: 4.200

6.  Prophylactic ranitidine treatment in critically ill children--a population pharmacokinetic study.

Authors:  Ahmed F Hawwa; Paul M Westwood; Paul S Collier; Jeffrey S Millership; Shirish Yakkundi; Gillian Thurley; Mike D Shields; Anthony J Nunn; Henry L Halliday; James C McElnay
Journal:  Br J Clin Pharmacol       Date:  2013-05       Impact factor: 4.335

Review 7.  Ranitidine. An updated review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in peptic ulcer disease and other allied diseases.

Authors:  S M Grant; H D Langtry; R N Brogden
Journal:  Drugs       Date:  1989-06       Impact factor: 9.546

8.  Ranitidine pharmacokinetics in newborn infants.

Authors:  M Fontana; E Massironi; A Rossi; P Vaglia; G P Gancia; P Tagliabue; N Principi
Journal:  Arch Dis Child       Date:  1993-05       Impact factor: 3.791

9.  Evaluation of Intravenous Ranitidine on Gastric pH in Critically Ill Pediatric Patients.

Authors:  Brady S Moffett; Lindsay Schmees; Kristina Gutierrez; Christian Erikson; Andrew Chu; Jorge A Coss-Bu; Nathan Strobel
Journal:  J Pediatr Pharmacol Ther       Date:  2019 Nov-Dec

10.  Pharmacokinetics of ranitidine in preterm and term neonates with gastroesophageal reflux.

Authors:  Ismael Lares Asseff; Graciela Benitez Gaucin; Hugo Juárez Olguín; Jose Antonio Godinez Nájera; Alejandra Toledo López; Gabriela Pérez Guillé; Fausto Zamura Torres
Journal:  BMC Pediatr       Date:  2016-07-13       Impact factor: 2.125

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.